Scopus Biopharma, Inc. · OTC:SCPS
Scopus Biopharma — Investor Presentation (December 2020)
19 slides from Scopus Biopharma's investor presentation, December 2020
Slide 1: Corporate Presentation December 2020
Corporate Presentation December 2020
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding Scopus BioPharma Inc., “Scopus” or the “Company” that are not historical fact, including, but not limited to, statements regarding ex
Slide 3: The Company
The Company ➢ Scopus BioPharma is developing CO-sTiRNATM, a ground-breaking cancer treatment encompassing both immunotherapy and gene therapy ➢ IND for Phase 1 clinical trial for B-cell Non-Hodgkin’s Lymphoma (“NHL”) slated to be filed in H1 2021 ➢ Clinical trial anticipated to begin in H2 2021 ➢ CO
Slide 4: The Company
The Company ➢ Subsequent Phase 1 clinical trial expected for B-cell NHL in combination with immune checkpoint inhibitors and/or CAR-Ts ➢ We have an exclusive worldwide license for CO-sTiRNA from City of Hope National Medical Center (“COH”), a world-renowned research and cancer center near Los Angele
Slide 5: Highlights
Highlights ➢ CO-sTiRNA is a potential game-changing treatment, making STAT3 “druggable” ➢ Unique approach encompassing both immunotherapy and gene therapy ➢ H1 2021 filing of IND and H2 2021 initiation of Phase 1 clinical trial for CO-sTiRNA ➢ Near-term milestones provide multiple opportunities to d
Slide 6: Pipeline
AKA SCOPUS Pipeline BIOPHARMA Program cat ate Pre-Clinical Testing +) IND-Enabling Studies +) rose) I CO-sTIRNA B-cell Non-Hodgkin's Lymphoma J i B-cell Non-Hodgkin's Lymphoma : Cutaneous T-cell Lymphoma | Other Solid Tumors dl MRI-1867 Systemic Sclerosis
Slide 7: Near-Term Value Building Milestones
Near-Term Value Building Milestones Q1 2021 Completion of clinical lot manufacturing Finalization of status report on research for CO-sTiRNA + checkpoint inhibitor under the SRA Finalization of IND package for CO-sTiRNA for B-cell NHL Q2 2021 Filing of IND for CO-sTiRNA for B-cell NHL with t
Slide 8: Additional Value Building Milestones
Additional Value Building Milestones 2022 Completion of supporting studies for CO-sTiRNA + checkpoint inhibitor Filing/amendment of IND for CO-sTiRNA + checkpoint inhibitor for Phase 1 clinical trial Commencement of CO-sTiRNA + checkpoint inhibitor Phase 1 clinical trial 8
Slide 9: Strategic Partners and Intellectual Property
Strategic Partners and Intellectual Property ➢ We capitalize on outstanding scientific and medical provenance based on pioneering discoveries at some of the world’s foremost research and academic institutions ➢ Exclusive worldwide licenses from COH, NIH and The Hebrew University of Jerusalem ➢ Our k
Slide 10: Experienced Biopharma Leadership
Experienced Biopharma Leadership Ashish P. Sanghrajka President and Director Aharon Schwartz, Ph.D. SAB Chairman Executive Chairman - Scopus Israel Morris C. Laster, M.D. SAB Member; Director and Senior Medical Advisor - Scopus Israel Raphael (Rafi) Hofstein, Ph.D. Director Nominee Lesley Russell, M
Slide 11: Experienced Finance and Capital Markets Leadership
Experienced Finance and Capital Markets Leadership Joshua R. Lamstein Chairman and Director Robert J. Gibson, CFA Vice Chairman and Director David S. Battleman, M.D. Director Nominee David A. Buckel, CMA Director Nominee Ira Scott Greenspan Director Paul E. Hopper Director David Weild IV Director No
Slide 12: CO-sTiRNA: A Cancer Therapeutic Drug Candidate with Dual Activity
CO-sTiRNA: A Cancer Therapeutic Drug Candidate with Dual Activity ➢ Dual activity blocks STAT3 in cancer cells and in tumor-associated immune cells while inducing antitumor immune responses ✓ Signal Transducer and Activator of Transcription 3 (STAT3) is a highly desirable target for cancer therapy.
Slide 13: Why Targeting STAT3 is So Important for Cancer Therapy
Why Targeting STAT3 is So Important for Cancer Therapy ➢ STAT3 is a critical convergence point for many cancer-causing pathways, promoting cancer cell survival, proliferation and invasion by regulating several genes involved in cell growth and division ➢ When STAT3 proteins are activated by various
Slide 14: Blocking STAT3 in the Presence of CpG Induces Potent Antitumor Immune Responses
Blocking STAT3 in the Presence of CpG Induces Potent Antitumor Immune Responses Proof-of-concept study in genetic model of STAT3 deletion (Mx-Cre/STAT3flox): STAT3 was removed from immune cells such as myeloid cells (DC, TAM, MDSC) and B cells but not from T cells B16 Melanoma Model Wild type contro
Slide 15: CO-sTiRNA: Pharmacology and Toxicology Studies
CO-sTiRNA: Pharmacology and Toxicology Studies ➢ No Cytokine Release Syndrome in vitro (human PBMC), no gross abnormalities in mouse and rat toxicology studies ➢ Completed initial toxicology study with CO-sTiRNA injected subcutaneously into male and female rats ➢ Subcutaneous injection (in rodents)
Slide 16: Overview of Phase 1 Clinical Trial for CO-sTiRNA
Overview of Phase 1 Clinical Trial for CO-sTiRNA Indication Non-Hodgkin’s Lymphoma Population/ Indication(s): Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma Phase Phase 1, with expansion cohort Segment Relapsed/ Recurrent Therapy Status At initial treatment No. of Patients 15 expected (4-24) Esti
Slide 17: MRI-1867
MRI-1867 ➢ MRI-1867 is a proprietary, dual-action, peripherally-restricted NCE CB1 receptor (CB1R) inverse agonist and inhibitor of iNOS ➢ Over activation of CB1 and iNOS has been implicated in the pathophysiology of systemic sclerosis, including fibrosis of the skin, lung, kidney and heart ➢ Modula
Slide 18: Key Takeaways
Key Takeaways ➢ Potential game-changing treatment making STAT3 “druggable” ➢ CO-sTiRNA stands out as both immunotherapy and gene therapy ➢ Value-driving, near-term milestones ➢ Multi-billion dollar market opportunities ➢ High barriers to entry ➢ Attractive drug candidates with moderate near-term cap
Slide 19: Thank You
KA SCOPUS BIOPHARMA Thank You
Scopus BioPharma — Investor Presentation (December 2020) on 6ix